>
Switch to:

Travere Therapeutics EPS (Diluted)

: $-3.37 (TTM As of Dec. 2020)
View and export this data going back to 2003. Start your Free Trial

Travere Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2020 was $-2.37. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was $-3.37.

Travere Therapeutics's EPS (Basic) for the three months ended in Dec. 2020 was $-2.37. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2020 was $-3.37.

Travere Therapeutics's EPS without NRI for the three months ended in Dec. 2020 was $-2.37. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2020 was $-3.37.

During the past 3 years, the average EPS without NRIGrowth Rate was -32.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, Travere Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 29.70% per year. The lowest was -172.10% per year. And the median was -32.20% per year.


Travere Therapeutics EPS (Diluted) Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.

* Premium members only.

Travere Therapeutics Annual Data
Feb11 Feb12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EPS (Diluted) Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.29 -1.54 -2.54 -3.46 -3.56

Travere Therapeutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
EPS (Diluted) Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.70 0.02 -0.58 -0.44 -2.37

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Travere Therapeutics EPS (Diluted) Distribution

* The bar in red indicates where Travere Therapeutics's EPS (Diluted) falls into.



Travere Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Travere Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2020 is calculated as

Diluted EPS (A: Dec. 2020 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-169.431-0)/47.540
=-3.56

Travere Therapeutics's Diluted EPS for the quarter that ended in Dec. 2020 is calculated as

Diluted EPS (Q: Dec. 2020 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-121.622-0)/51.291
=-2.37

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was 0.02 (Mar. 2020 ) + -0.58 (Jun. 2020 ) + -0.44 (Sep. 2020 ) + -2.37 (Dec. 2020 ) = $-3.37

* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.


Travere Therapeutics  (NAS:TVTX) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Travere Therapeutics EPS (Diluted) Related Terms


Travere Therapeutics EPS (Diluted) Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)